Prevalence of injection-meal interval usage and its association with variables of metabolic control in patients with Type 1 and Type 2 diabetes

Diabetic Medicine

Volumn 28, Issue 2, 2011, Pages 223-226

  Muller N ^a   Kloos, C ^a   Frank, T ^b   Ristow, M ^c   Wolf, G ^a   Muller U A ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b Practice for General Medicine and Diabetology   (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Diabetes mellitus; HbA1c; Injection meal interval

Indexed keywords

HEMOGLOBIN A1C; INSULIN;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL TRIAL (TOPIC); DISEASE DURATION; FOOD INTAKE; HUMAN; INJECTION; INJECTION MEAL INTERVAL; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PREVALENCE;

ADULT; BASAL METABOLISM; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; EATING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; PREVALENCE;

EID: 78651111643     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2010.03172.x     Document Type: Article

References (15)

1. Federal Statistical Office. Health in Germany. Record of health of Federation. Berlin: Robert-Koch-Institut, 2006.
2. Hansen B, Altenhofen L, Haß W, Blaschy S, Kretschmann J. Report of the Disease Management Programmes 2007 in Northrhine: Breast Cancer, Diabetes Mellitus Type 2 and Type 2, Coronary Artery Disease, Asthma, COPD. Germany: KV Northrhine, 2008. Available at Last accessed 7 November 2010.
3. Bolli GB. Clinical strategies for controlling peaks and valleys: type 1 diabetes. Int J Clin Pract Suppl 2002; 129: 65-74.
4. Brunton S. Initiating insulin therapy in type 2 diabetes: benefits of insulin analogs and insulin pens. Diabetes Technol Ther 2008; 10: 247-256.
5. Müller UA, Femerling M, Reinauer KM, Risse A, Voss M, Jörgens V et al. Intensified treatment and education of type 1 diabetes as clinical routine. A nationwide quality-circle experience in Germany. ASD (the working group on structured diabetes therapy of the German diabetes association). Diabetes Care 1999; 22: B29-B34.
6. Galloway JA, Spradlin CT, Nelson RL, Wentworth SM, Davidson JA, Swarner JL. Factors influencing the absorption, serum insulin concentrations, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care 1981; 4: 366-376.
7. Berger M, Cüppers HJ, Hegner H, Jörgens V, Berchtold P. Absorption kinetics and biologic effects of subcutaneously injected insulin preparations. Diabetes Care 1982; 5: 77-91.
8. Kinmonth AL, Baum JD. Timing of pre-breakfast insulin injection and postprandial metabolic control in diabetic children. Br Med J 1980; 284: 604-606.
9. Witt MF, White MH, Santiago JV. Role of sites and timing of morning insulin injection in type 1 diabetes. J Pediatrics 1983; 103: 528-533.
10. Dimitriadis GD, Gerich JE. Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care 1983; 6: 374-377.
11. Lean ME, Ng LL, Tennison BR. Interval between insulin injection and eating in relation to blood glucose control in adult diabetics. Br Med J (Clin Res Ed) 1985; 290: 105-108.
12. Heinemann L. Do insulin-treated diabetic patients use an injection-meal-interval in daily life? Diabet Med 1995; 12: 449-454.
13. Scheen AJ, Letiexhe MR, Lefèbre PJ. Minimal influence of the time interval between injection of regular insulin and food intake on blood glucose control of type 1 diabetic patients on a basal-bolus insulin scheme. Diabetes Metab 1999; 25: 157-162.
14. Ashwell SG, Bradley C, Stephens JW, Witthaus E, Home PD. Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in individuals with Type 1 diabetes. Diabetes Care 2008; 31: 1112-1117.
15. Gale EAM. A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy. Diabetic Med 2000; 17: 209-214.